⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024

Figure S5 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O’Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclová Matthew J. Martin Ludovic Bigot Luc Friboulet Ryan J. Hartmaier Maria Emanuela Cuomo Simon T. Barry Paul D. Smith Nicolas Floc’h

View at Publisher

Ask AI

Bookmark

Share

Abstract

Figure S5: Percentage change in mouse body weight across the in vivo studies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grazini et al. (2024) studied this question.

synapsesocial.com/papers/68e58a5ab6db64358752645b https://doi.org/10.1158/1078-0432.27013634

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
2Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
3Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
4Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
5Figure S2 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024

Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Figure S7 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
Data from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024